Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.

Journal of theoretical biology - 21 Jan 2016

Sameen Sheema, Barbuti Roberto, Milazzo Paolo, Cerone Antonio, Del Re Marzia, Danesi Romano

Abstract excerpt

The most challenging task in colorectal cancer research nowadays is to understand the development of acquired resistance to anti-EGFR drugs. The key reason for this problem is the KRAS mutations appearance after the treatment with monoclonal antibodies (moAb). Here we present a mathematical model for the analysis of KRAS mutations behavior in colorectal cancer with respect to moAb treatments. To evaluate the drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Cetuximab
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune System

Share to Irinotecan

Share to Lymphocytes

Share to Models, Theoretical

Share to Stochastic Processes

Source

Identifiers

PMID: 26551156
DOI: 10.1016/j.jtbi.2015.10.019

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.PMID 26551156Read ↗

Mathematical modeling the order of driver gene mutations in colorectal cancer.Semantic proximity Read ↗

Drug resistance in cancer mechanisms and modelsSemantic proximity Read ↗

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Semantic proximity Read ↗

Computational quantification of global effects induced by mutations and drugs in signaling networks of colorectal cancer cells.Semantic proximity Read ↗

Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.Semantic proximity Read ↗

A quantitative systems pharmacology analysis of KRAS G12C covalent inhibitorsSemantic proximity Read ↗

Modeling multi-mutation and drug resistance: analysis of some case studies.Semantic proximity Read ↗

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].Semantic proximity Read ↗

An elementary mathematical modeling of drug resistance in cancer.Semantic proximity Read ↗

Stochastic modeling of drug resistance in cancer.Semantic proximity Read ↗

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.Semantic proximity Read ↗

An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.